In addition to their favorable therapeutic impacts on pulmonary arterial hypertension, PDE5 inhibitors have recently been shown to be effective therapeutics in patients with chronic systolic heart failure (SHF) [8,10]. Here, PDE5A is linked to pulmonary arterial hypertension.